SecBot SecBot
SECBOTREPLAY Home › Report › SNDX

SNDX · Syndax Pharmaceuticals issued $250 million aggregate principal amount…

Syndax Pharmaceuticals Inc · 8-K filed Jun 10, 2026 at 17:04 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Jun 10, 2026 at 17:04 ET

Syndax Pharmaceuticals issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031 in a private placement, generating net proceeds of approximately $243 million. The company plans to use the funds for general corporate purposes including R&D, commercialization, and business development. The notes are convertible into common stock at an initial rate of 40.3894 shares per $1,000 principal, with a maximum potential dilution of up to 13,631,400 shares.

  • Issued $250 million aggregate principal amount of 2.25% Convertible Senior Notes due 2031
  • Net proceeds of approximately $243 million after fees and expenses
  • Initial conversion rate of 40.3894 shares per $1,000 principal amount of Notes
  • Maximum of 13,631,400 shares of common stock may be issued upon conversion

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access